Sections
| Title | Starting Page | Number of Pages |
|---|
| COVER | 1 | 4 |
| PLUNKETT S BIOTECH &GENETICS INDUSTRY ALMANAC 2013 | 5 | 4 |
| CONTENTS | 9 | 2 |
| A Short Biotech &Genetics Industry Glossary | 11 | 20 |
| INTRODUCTION | 31 | 2 |
| HOW TO USE THIS BOOK | 33 | 4 |
| Chapter 1 MAJOR TRENDS AFFECTING THE BIOTECH &GENETICS INDUSTRY | 37 | 39 |
| 1) The State of the Biotechnology Industry Today | 38 | 5 |
| 2) A Short History of Biotechnology | 43 | 1 |
| 3) Ethanol Production Soars, But U.S. Federal Subsidy in Question | 44 | 3 |
| 4) Major Drug Companies Bet on Partnerships With Smaller Biotech Research Firms | 47 | 1 |
| 5) From India to Singapore to China, Nations Compete Fiercely in Biotech Development | 48 | 2 |
| 6) Clinical Trials and Medical Records Processing Conducted Abroad Spark Concerns | 50 | 1 |
| 7) Gene Therapies and Patients Genetic Profiles Promise a Personalized Approach to Medicine | 51 | 3 |
| 8) Breakthrough Drugs for Cancer Treatment Many More Will Follow | 54 | 1 |
| 9) Few New Blockbusters: Major Drug Patents Expire While Generic Sales Growth Continues | 55 | 2 |
| 10) Biotech and Orphan Drugs Pick Up the Slack as Blockbuster Mainstream Drugs Age | 57 | 1 |
| 11) Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce | 58 | 2 |
| 12) Breakthrough New Drug Delivery Systems Evolve | 60 | 1 |
| 13) Stem Cells Multiple Sources Stem from New Technologies | 60 | 2 |
| 14) Government Support for New Stem Cell Research Evolves | 62 | 1 |
| 15) Stem Cells Therapeutic Cloning Techniques Advance | 63 | 2 |
| 16) Stem Cells A New Era of Regenerative Medicine Takes Shape | 65 | 2 |
| 17) Nanotechnology Converges with Biotech | 67 | 1 |
| 18) Agricultural Biotechnology Scores Breakthroughs but Causes Controversy/Selective Breeding Offers a Compromise | 68 | 3 |
| 19) Focus on Vaccines | 71 | 1 |
| 20) Technology Discussion Genomics | 72 | 1 |
| 21) Technology Discussion Proteomics | 72 | 1 |
| 22) Technology Discussion Microarrays | 73 | 1 |
| 23) Technology Discussion DNA Chips | 73 | 1 |
| 24) Technology Discussion SNPs ( Snips ) | 74 | 1 |
| 25) Technology Discussion Combinatorial Chemistry | 74 | 1 |
| 26) Technology Discussion Synthetic Biology | 74 | 1 |
| 27) Technology Discussion Recombinant DNA | 75 | 1 |
| 28) Technology Discussion Polymerase Chain Reaction (PCR) | 75 | 1 |
| Chapter 2 BIOTECH &GENETICS INDUSTRY STATISTICS | 76 | 21 |
| Biotech Industry Overview | 77 | 1 |
| The U.S. Drug Discovery &Approval Process | 78 | 1 |
| U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2011 | 79 | 1 |
| U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2011 | 80 | 1 |
| Employment in Life &Physical Science Occupations, U.S.: May 2011 | 81 | 1 |
| Federal R&D &R&D Plant Funding for General Science &Basic Research, U.S.: Fiscal Years 2011-2013 | 82 | 1 |
| U.S. Exports &Imports of Pharmaceutical Products: 2007-1st Quarter 2012 | 83 | 1 |
| U.S. Prescription Drug Expenditures, Aggregate &Per Capita Amounts, Percent Distribution: 2006-2021 | 84 | 2 |
| U.S. Prescription Drug Expenditures: 1970-2021 | 86 | 2 |
| Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2011 | 88 | 1 |
| Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2011-2013 | 89 | 1 |
| Global Area of Biotech Crops by Country: 2011 | 90 | 1 |
| Biologics &Biotechnology R&D, PhRMA Member Companies: 2010 | 91 | 1 |
| Domestic &Foreign Pharmaceutical Sales, PhRMA Member Companies: 1975-2011 | 92 | 1 |
| Sales By Geographic Area, PhRMA Member Companies: 2010 | 93 | 1 |
| Domestic U.S. Biopharmaceutical R&D Breakdown,PhRMA Member Companies: 2010 | 94 | 1 |
| Domestic Biopharmaceutical R&D Scientific, Professional &Technical Personnel by Function, PhRMA Member Companies: 2010 | 95 | 1 |
| Domestic U.S. Biopharmaceutical R&D &R&D Abroad, PhRMA Member Companies: 1975-2011 | 96 | 1 |
| Chapter 3 IMPORTANT BIOTECH &GENETICS INDUSTRY CONTACTS | 97 | 39 |
| Chapter 4 THE BIOTECH 350: WHO THEY ARE AND HOW THEY WERE CHOSEN | 136 | 380 |
| INDUSTRY LIST, WITH CODES | 137 | 1 |
| INDEX OF COMPANIES WITHIN INDUSTRY GROUPS | 138 | 8 |
| ALPHABETICAL INDEX | 146 | 3 |
| INDEX OF U.S. HEADQUARTERS LOCATION BY STATE | 149 | 3 |
| INDEX OF NON-U.S. HEADQUARTERS LOCATION BY COUNTRY | 152 | 2 |
| INDEX BY REGIONS OF THE U.S. WHERE THE FIRMS HAVE LOCATIONS | 154 | 6 |
| INDEX OF FIRMS WITH INTERNATIONAL OPERATIONS | 160 | 2 |
| Individual Profiles On Each Of THE BIOTECH 350 | 162 | 354 |
| ADDITIONAL INDEXES | 516 | 1 |
| INDEX OF FIRMS NOTED AS HOT SPOTS FOR ADVANCEMENT FOR WOMEN &MINORITIES | 517 | 2 |
| INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS | 519 | 19 |
